Pohl-Guimarães Fernanda, Hoang-Minh Lan B, Mitchell Duane A
Preston A. Wells, Jr. Center for Brain Tumor Therapy, UF Brain Tumor Immunotherapy Program, McKnight Brain Institute, Department of Neurosurgery, University of Florida, Gainesville, FL, USA.
Oncoimmunology. 2020 Oct 7;9(1):1792625. doi: 10.1080/2162402X.2020.1792625.
Adoptive T cell therapy has proven effective against hematologic malignancies and demonstrated efficacy against a variety of solid tumors in preclinical studies and clinical trials. Nonetheless, antitumor responses against solid tumors remain modest, highlighting the need to enhance the effectiveness of this therapy. Genetic modification of T cells with RNA has been explored to enhance T-cell antigen specificity, effector function, and migration to tumor sites, thereby potentiating antitumor immunity. This review describes the rationale for RNA-electroporated T cell modifications and provides an overview of their applications in preclinical and clinical investigations for the treatment of hematologic malignancies and solid tumors.
过继性T细胞疗法已被证明对血液系统恶性肿瘤有效，并在临床前研究和临床试验中显示出对多种实体瘤的疗效。尽管如此，针对实体瘤的抗肿瘤反应仍然有限，这突出了提高这种疗法有效性的必要性。人们已经探索了用RNA对T细胞进行基因改造，以增强T细胞抗原特异性、效应功能以及向肿瘤部位的迁移，从而增强抗肿瘤免疫力。本综述描述了RNA电穿孔T细胞改造的基本原理，并概述了其在治疗血液系统恶性肿瘤和实体瘤的临床前和临床研究中的应用。
